Take2 Health Teaming Up with Yourgene Health to Expand its Service to Taiwan Region
Take2 Health (“Take2”) and Yourgene Health (“Yourgene”) have reached a partnership to offer the clinically-validated Take2 Prophecy™ Test for Nasopharyngeal Cancer (“NPC”) in Taiwan region, as well as to establish a medical network for the collection of clinical specimens. In addition, the two parties have signed a Memorandum of Understanding to consider granting rights to allow Yourgene to perform the test in its local laboratory.
Under the agreement, Take2 aims to facilitate early diagnosis and timely treatments of NPC with Yourgene’s extensive region-wide medical service networks. Yourgene will be responsible for driving local clinical demand, working with clinicians and healthcare professionals in promoting early cancer detection, and advocating its importance to the general public.
Yourgene is an international molecular diagnostics group headquartered in Manchester, UK, with offices in Taiwan region, Singapore, the U.S. and Canada and is listed on the London Stock Exchange. The partnership with Yourgene lays the cornerstone for commercialising ground-breaking technologies for both signing parties in the future.
More Latest News
Nasopharyngeal Cancer Screening Results May “Predict” Development of Related Cancer and Improve Early Diagnosis, CUHK Study Finds
A recent study conducted by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has shown that individuals with detectable plasma Epstein–Barr virus (EBV) DNA but without an immediately identifiable nasopharyngeal cancer (NPC) after further investigation with nasal endoscopic examination and magnetic resonance imaging (MRI), have a higher risk of developing NPC in 3 to 5 years, up to 17 times higher than those tested “negative” in the test. The non-invasive liquid biopsy techniques not only could be used for early cancer detection but may also indicate the risk for future cancer development.
Promoting NPC Awareness across the City
Joining Hands with Bowtie to Sponsor the Take2 Prophecy™ Test for Nasopharyngeal Cancer to the High-risk Group
Awarded as The Company with the Most Investment Potential & The Top Breakthrough Innovation
Take2 Health are privileged to have participated in the first ZAODX World Conference on Early Detection of Cancer, and are very honoured to be awarded as The Company with the Most Investment Potential (金篩獎‧最具投資價值潛力企業) as well as The Top Breakthrough Innovation (金篩獎‧突破性創新獎)
